A comparison of hepatitis C treatment and outcomes at academic, private and Veterans' Affairs treatment centres

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 1, 2004, Pages 69-77

  Jensen, D M ^a   Cotler, S J ^a   Lam, H ^b   Harb, G ^c   Shillington, A ^d  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b Department of Rheumatology   (United States)

^c HOFFMANN LA ROCHE INC   (United States)

^d EPI Q Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2B INTERFERON; ANTIVIRUS AGENT; RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; AGED; ANEMIA; ANXIETY DISORDER; ARTICLE; CLINICAL PRACTICE; CLINICAL TRIAL; COHORT ANALYSIS; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DRUG COMBINATION; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; FLU LIKE SYNDROME; GENOTYPE; HEPATITIS C; HUMAN; INSOMNIA; IRRITABILITY; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPENIA; ORGANIZATION AND MANAGEMENT; PRIORITY JOURNAL; PUBLIC HOSPITAL; RETROSPECTIVE STUDY; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT FAILURE; TREATMENT OUTCOME; UNIVERSITY HOSPITAL; UTILIZATION REVIEW;

ACADEMIC MEDICAL CENTERS; ADULT; AGED; ANTIVIRAL AGENTS; COHORT STUDIES; DRUG COMBINATIONS; FEMALE; HEPATITIS C; HOSPITALS, VETERANS; HUMANS; INTERFERON ALFA-2B; MALE; MIDDLE AGED; PRIVATE SECTOR; RETROSPECTIVE STUDIES; RIBAVIRIN; TREATMENT OUTCOME;

EID: 1642533526     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.2003.01817.x     Document Type: Article

References (15)

1. Herrera JL. The role of the primary care provider in diagnosing and managing chronic hepatitis C. Prev Med Manag Care 2000; 1(Suppl.): S22-32.
2. Sterling RK, Schiffman MI. Acute and chronic viral hepatitis. In: Rakel RE, ed. Conn's Current Therapy 2000. Philadelphia: W.B. Saunders, 2000: 501-7.
3. Alter MJ. Epidemiology of hepatitis C. Hepatology 1997; 26(3 Suppl. 1): 62S-65S.
4. Centers for Disease Control and Prevention. Recommendations for prevention and control of hepatitis C virus (HCV) infection and HCV-related chronic disease. MMWR Recomm Rep 1998; 47(RR-19): 1-39.
5. Scott LJ, Perry CM. Interferon-alpha-2b plus ribavirin: a review of its use in the management of chronic hepatitis C. Drugs 2002; 62: 507-56.
6. McHutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. N Engl J Med 1998; 339: 1485-92.
7. Poynard T, Marcellin P, Lee SS, et al. Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 1998; 352: 1426-32.
8. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001; 358: 958-65.
9. Fried MW, Shiffman ML, Reddy RK, et al. Pegylated (40 kDa) interferon alfa-2a (PEGASYS) in combination with ribavirin: efficacy and safety results from a phase III. randomized. actively-controlled, multicenter study. In: Proceedings of the American Association for the Study of Liver Disease (AASLD) Presidential Plenary Session, Atlanta, GA, USA. Philadelphia: 2001: Abstract 289.
10. Garcia FA, Miller HB, Huggins GR, et al. Effect of academic affiliation and obstetric volume on clinical outcome and cost of childbirth. Obstet Gynecol 2001; 97: 567-76.
11. Turner BJ, Amsel Z, Lustbader E, et al. Breast cancer screening: effect of physician specialty, practice setting, year of medical school graduation, and sex. Am J Prev Med 1992; 8: 78-85.
12. Harnick DJ, Cohen JL, Schechter CB, et al. Effects of practice setting on quality of lipid-lowering management in patients with coronary artery disease. Am J Cardiol 1998; 81: 1416-20.
13. Kruskal W, Wallis W. Use of ranks in one-criterion variance analysis. J Am Stat Assoc 1952; 47: 583-621.
14. Reddy KR, Hoofnagle JH, Tong MJ, et al. Racial differences in responses to therapy with interferon in chronic hepatitis C. Consensus Interferon Study Group. Hepatology 1999; 30: 787-93.
15. De Amici D, Klersy C, Ramajoli F, et al. Impact of the Hawthorne effect in a longitudinal clinical study: the case of anesthesia. Controlled Clin Trials 2000; 21: 103-14.